Recombinant human CD80 mutant -Fc fusion protein

重组人CD80突变体-Fc融合蛋白

Report date: 2023/02/17 10:03:53

Base Information

Drug NameRecombinant human CD80 mutant -Fc fusion protein
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXuanzhu (Shijiazhuang) Biotechnology Co LtdBeijing Xuanzhu Kangming Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Xuanzhu Kangming Biotechnology Co LtdXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A